Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatment with rio...

Full description

Bibliographic Details

Main Authors:	Marra, Alberto M. (Author) , Benjamin, Nicola (Author) , Eichstaedt, Christina (Author) , Egenlauf, Benjamin (Author) , Harutyunova, Satenik (Author) , Fischer, Christine (Author) , Grünig, Ekkehard (Author)
Format:	Article (Journal)
Language:	English
Published:	19 December 2018
In:	Respiratory research Year: 2018, Volume: 19
ISSN:	1465-993X
DOI:	10.1186/s12931-018-0957-y
Online Access:	Verlag, Volltext: https://doi.org/10.1186/s12931-018-0957-y
Author Notes:	Alberto M. Marra, Michael Halank, Nicola Benjamin, Eduardo Bossone, Antonio Cittadini, Christina A. Eichstaedt, Benjamin Egenlauf, Satenik Harutyunova, Christine Fischer, Henning Gall, Hossein Ardeschir Ghofrani, Marius M. Hoeper, Tobias J. Lange, Karen M. Olsson, Hans Klose and Ekkehard Grünig